Loading insider details...
Beta
Latest Form 4 (Feb 24, 2026): Grant/Award of 12,050 NGNE shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Feb 24, 2026 | Neurogene Inc. (NGNE) | Grant/Award | 12,050 | n/a |
| Jun 13, 2025 | Neurogene Inc. (NGNE) | Grant/Award | 12,050 | n/a |
| Jun 9, 2025 | Metagenomi, Inc. (MGX) | Sale | 5,239 | $9.2K |
| Apr 3, 2025 | Metagenomi, Inc. (MGX) | Grant/Award | 14,000 | n/a |
| Jun 20, 2024 | MARINUS PHARMACEUTICALS, INC. (MRNS) | Grant/Award | 2,300 | n/a |
| Jun 17, 2024 | Neurogene Inc. (NGNE) | Grant/Award | 7,700 | n/a |
| Apr 4, 2024 | Metagenomi, Inc. (MGX) | Grant/Award | 57,763 | n/a |
| Jan 19, 2024 | MARINUS PHARMACEUTICALS, INC. (MRNS) | Grant/Award | 4,600 | n/a |
| Jan 18, 2024 | Neurogene Inc. (NGNE) | Grant/Award | 15,400 | n/a |
| Jun 9, 2023 | Neoleukin Therapeutics, Inc. (NLTX) | Grant/Award | 25,000 | n/a |